Conflicting verdicts on peanut oral immunotherapy from the Institute for Clinical and Economic Review and US Food and Drug Administration Advisory Committee: Where do we go from here?

Thomas Eiwegger, Katherine Anagnostou, Stefania Arasi, Philippe Bégin, Moshe Ben-Shoshan, Kirsten Beyer, Katharina Blumchen, Helen Brough, Jean Christoph Caubet, Edmond S. Chan, Meng Chen, Sharon Chinthrajah, Carla M. Davis, Anne Des Roches, George Du Toit, Arnon Elizur, Stephen J. Galli, Geir Håland, Karin Hoffmann-Sommergruber, Harold KimDonald Y.M. Leung, Andrew Long, Antonella Muraro, Ulugbek B. Nurmatov, Giovanni B. Pajno, Vanitha Sampath, Jamie Saxena, Sayantani Sindher, Julia Upton, Margitta Worm, Kari C. Nadeau*

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

13 Citations (Scopus)
Original languageEnglish
JournalJournal of Allergy and Clinical Immunology
DOIs
Publication statusPublished - 1 Jan 2019

Keywords

  • efficacy
  • Food allergy
  • Institute for Clinical and Economic Review
  • management
  • peanut allergy
  • quality of life
  • safety
  • treatment
  • US Food and Drug Administration Allergenic Products Advisory Committee

Cite this